Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • tdm logo
      tdm logo

      AbbVie offers Therapeutic Drug Monitoring (TDM) to support your patients

      TDM is increasingly considered the standard of care in Australia1, yet government funding is only available in selected jurisdictions. 

      AbbVie provides fully subsidised TDM and adalimumab antibody testing (if required*) for eligible HUMIRA (adalimumab) patients to ensure all Australians can access TDM, where deemed clinically necessary. 

      To access TDM, please complete the eligibility check below, and provide your patient with the SONIC Pathology Request form. 

      *If adalimumab levels are <0.5mg/mL, anti-adalimumab antibody testing will be performed.

      Check your patient's eligibility for TDM support

      Please complete the following fields and submit your request to confirm your patient's eligibility.

      Prescribing Gastroenterologist details

      Please read and acknowledge that the following the following Terms and Conditions and Privacy information are understood:

      * I must provide my patient with a SONIC laboratories pathology form specifically marked for the test(s) to be fully subsidised by AbbVie. 
      * I will receive my patient's test results directly from SONIC laboratories. Test results will not be shared with AbbVie or its nominated Service Providers. 
      * You as the prescribing gastroenterologist are responsible for determining the clinical needs of the patient & monitoring the outcome of any treatment options. You are also responsible for ensuring that the patient has provided informed consent prior to undertaking Therapeutic Drug Monitoring. 
      * Prescribing Specialists and Healthcare Professionals should also be aware of and consent to the Healthcare Professional Privacy Notice.

      View full terms and conditions
      Hide full terms and conditions
      Contact a rep
      Contact a rep

      More for you

      About HUMIRA
      About HUMIRA

      Learn more

      Education
      Education

      Keep your professional development current

      Education
      Services

      Support for you and your patients

      Your decisions have transformed the
      lives of many patients

      AbbVie and HUMIRA - your partners on the journey.*

      *AbbVie medications and programs are designed to support patients on their health journey.

      Your decisions have transformed the lives of many patients

      AbbVie and HUMIRA - your partners on the journey.*

      *AbbVie medications and programs are designed to support patients on their health journey.

      TDM: therapeutic drug monitoring. WA: Western Australia.

      Reference: 1. Mitrev N et al. Aliment Pharmacol Ther 2017;46(11-12):1037-53.

      PBS Information

      HUMIRA: Authority required. Refer to PBS Schedule for full authority information. This product is not listed on the PBS for the treatment of enthesitis-related arthritis or paediatric psoriasis.

      Please review the full Product Information (PI) before prescribing, available below.

      HUMIRA PI

      AU-HUM-220121. February 2024